US FDA Wants ‘Minor’ Labeling Changes For OTCs Available Through NDAs/ANDAs In Annual Reports

Fewer labeling changes submitted for OTC NDAs/ANDAs makes more time available for CDER reviews of other applications for OTC switches as well as non-minor labeling changes to nonprescription drugs plus far larger number of submissions for Rx drug approvals and labeling.